FDA Extends DSCSA Exemption For Small Pharmacies Through November 27, 2027: What Pharmacies Need To Know

The Food and Drug Administration (FDA) has provided small pharmacies with additional time to comply with certain enhanced drug distribution security requirements under the Drug Supply Chain Security Act (DSCSA). The extension is significant for independent pharmacies that have been working through the operational, technological and financial challenges associated with implementing the DSCSA’s electronic and interoperable drug tracing requirements.

FDA has extended certain DSCSA exemptions for qualifying small dispensers, including pharmacies, through November 27, 2027. The original compliance date was November 27, 2026.

Importantly, however, pharmacies should not interpret the extension as a suspension of the DSCSA requirements that are already in effect, even for small dispensers. Small pharmacies should also not view this extension as an opportunity to put ongoing implementation efforts on hold. FDA expressly continues to encourage small dispensers to implement the systems and processes necessary to comply with the enhanced drug distribution security requirements.

The practical message for pharmacies is straightforward: qualifying small pharmacies have additional time, but that time should be used to prepare for full compliance.

What Is the DSCSA?

Congress enacted the DSCSA to establish a more secure and traceable prescription drug distribution system in the United States. The law requires pharmaceutical trading partners, including manufacturers, repackagers, wholesale distributors and dispensers, to maintain systems designed to identify and trace certain prescription drugs as they move through the pharmaceutical supply chain.

The ultimate objective is an interoperable, electronic system capable of tracing prescription drugs at the package level.

For pharmacies, DSCSA compliance involves considerably more than simply retaining wholesaler invoices. Depending on the applicable requirement, pharmacies must be able to receive, maintain, and retrieve transaction information and transaction statements; investigate suspect products; respond appropriately when illegitimate products are identified and exchange required information with authorized trading partners.

As the industry moved toward implementation of the enhanced requirements under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), it became increasingly clear that smaller pharmacies faced practical challenges that were materially different from those confronting large pharmacy chains and other sophisticated trading partners.

FDA has responded by providing certain exemptions and additional implementation time.

Who Qualifies as a Small Dispenser?

The definition is critical.

For purposes of FDA’s current exemption, a dispenser is considered a “small dispenser” if, as of November 27, 2026, the company that owns the dispenser has 25 or fewer full-time employees who are licensed pharmacists or qualified pharmacy technicians.

This distinction deserves particular attention.

The analysis is not necessarily limited to the number of employees physically working at one pharmacy location. FDA’s formulation looks to the company that owns the dispenser. Pharmacy organizations operating multiple locations, therefore, should carefully evaluate their organizational structure and employee counts before assuming that each individual pharmacy independently qualifies for the exemption. This can become particularly important for pharmacy groups operating through affiliated entities, holding companies or multiple pharmacy locations.

Status as a small dispenser is also time-linked to November 27, 2026. This is a change from the earlier requirement. The original November 27, 2026 small dispenser compliance deadline anchored the size determination to a look-back date of November 27, 2024. By extending the compliance date for small dispensers for one additional year, FDA has now also updated the point in time at which small dispenser status must be determined.

Pharmacies should document the basis for their determination that they qualify as a small dispenser. Although FDA does not require qualifying pharmacies to submit a request or notification to rely on the exemption, maintaining internal documentation supporting eligibility is prudent from a compliance perspective.

What Did FDA Extend?

FDA is exercising its authority under Section 582(a)(3) of the FD&C Act to exempt qualifying small dispensers, and where applicable their trading partners, from certain Section 582 requirements through November 27, 2027. The extension provides small pharmacies additional time while FDA completes its assessment of small dispensers, publishes a final assessment report for public comment and conducts a public meeting regarding that assessment. This is noteworthy because the extension reflects FDA’s continued recognition that implementation of the enhanced DSCSA requirements presents unique challenges for smaller pharmacy operations.

FDA is also encouraging small dispensers to participate in its small dispenser assessment survey by September 22, 2026. FDA permits pharmacies to designate another entity, including a consultant, to complete the survey on their behalf.

The assessment may ultimately provide FDA with additional information concerning the technological, operational, and economic realities facing independent pharmacies as the agency considers implementation of the DSCSA requirements.

Pharmacies Do Not Need to Apply for the Small Dispenser Exemption

One important aspect of the exemption is that qualifying small dispensers do not have to submit an individual application to FDA.

FDA specifically states that small dispensers and their trading partners relying on the exemption do not need to submit anything to FDA or otherwise notify the agency. That should be distinguished from an individualized waiver, exception, or exemption request.

Trading partners that do not qualify for the small dispenser exemption and cannot satisfy applicable enhanced drug distribution security requirements may request relief directly from FDA. Depending on the circumstances, Section 582 permits FDA to grant waivers, exceptions or exemptions from particular requirements. Those requests require considerably more analysis and supporting documentation.

What If a Pharmacy Does Not Qualify?

A pharmacy that does not qualify for the small dispenser exemption should not simply assume that additional time is available.

FDA permits trading partners that cannot satisfy applicable enhanced requirements to request a waiver, exception or exemption. FDA recommends that such requests include a detailed explanation supporting the request, relevant documentation, and any special circumstances involving the applicable product or transaction. FDA has also identified several categories of information that have been useful in evaluating previous requests. These include the steps already taken toward compliance, why additional time is necessary, the steps that will be taken to achieve full compliance and the number of full-time employees employed by the trading partner. The distinction between requesting relief and receiving relief is equally important.

Note that submitting a request does not, by itself, suspend the pharmacy’s compliance obligations. FDA expects the trading partner to continue its compliance efforts until FDA approves or denies the request. Accordingly, a pharmacy should not treat the filing of a waiver or exemption request as an automatic extension.

The Extension Until November 27, 2027 Is Not a Reason to Stop DSCSA Implementation

Perhaps the most important compliance point is what the exemption does not mean.

First and foremost, it does not eliminate the DSCSA. It also does not permanently exempt independent pharmacies from enhanced drug tracing requirements. Furthermore, the extension should not be viewed as authorization for pharmacies to abandon implementation efforts until November 2027.

FDA expressly urges small dispensers to continue implementing the measures necessary to comply with the enhanced drug distribution security requirements. That is important because DSCSA implementation can require coordination among pharmacies, wholesalers, technology vendors, PSAOs and other trading partners. A pharmacy waiting until the exemption approaches expiration may discover that technological integration, data remediation, employee training or trading partner coordination cannot realistically be completed in a matter of weeks.

There is also a broader compliance concern. Even where a pharmacy qualifies for relief from particular enhanced requirements, the exemption should not be interpreted as eliminating every obligation imposed by the DSCSA. Pharmacies should understand precisely which requirements are covered by an applicable exemption and which requirements remain operative.

What Pharmacies Should Be Doing Now

Independent pharmacies should use the additional implementation period strategically.

• First, pharmacies should determine and document whether they satisfy FDA’s definition of a small dispenser, noting the November 27, 2026 anchor date for that determination. Multi-location pharmacy organizations should pay particular attention to their ownership structure and employee count methodology.
• Second, pharmacies should identify which DSCSA requirements are covered by the exemption and which obligations remain applicable.
• Third, pharmacies should evaluate whether their existing pharmacy management systems and other technology can receive, store, retrieve and exchange the required electronic transaction information.
• Fourth, pharmacies should communicate with their wholesalers and other trading partners concerning DSCSA readiness. A pharmacy’s compliance infrastructure cannot operate in isolation because the DSCSA is fundamentally based upon the exchange of information throughout the pharmaceutical distribution supply chain.
• Fifth, pharmacies should review their written policies and procedures regarding suspect and illegitimate products, product investigations, quarantine procedures, record retention and communications with trading partners and regulators.
• Finally, pharmacies should train personnel. Technology is only one component of DSCSA compliance. Pharmacy employees must understand what to do when transaction information is missing, when a product appears suspicious or when the pharmacy receives a request for information relating to a product investigation.

The Bigger Picture for Independent Pharmacies

The latest extension is meaningful relief for qualifying independent pharmacies.

FDA appears to recognize that requiring a small independent pharmacy to implement the same technological infrastructure on the same timeline as a national organization can create substantial operational difficulties. The extension through November 27, 2027 gives qualifying pharmacies additional time while FDA further evaluates the impact of DSCSA implementation on small dispensers. However, pharmacies should use the extension for what it is: additional implementation time, not a permanent safe harbor.

DSCSA compliance is increasingly becoming part of the broader pharmacy compliance environment. Pharmacies already face scrutiny from Boards of Pharmacy, PBMs, wholesalers, manufacturers, PSAOs, Medicaid programs and other regulators and trading partners. Documentation concerning drug acquisition and the legitimacy of the pharmaceutical supply chain can arise in audits, investigations, credentialing reviews and enforcement matters well beyond an FDA inspection.

For that reason, pharmacies should not approach DSCSA compliance as an isolated federal requirement.

The better approach is to incorporate DSCSA requirements into the pharmacy’s overall compliance infrastructure, including purchasing protocols, inventory controls, wholesaler relationships, record retention procedures, employee training and audit response protocols.

For qualifying small pharmacies, FDA has now provided additional breathing room through November 27, 2027. The pharmacies that use that time to build the appropriate infrastructure will be in a substantially better position when the exemption ultimately ends.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.